Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (November 2024)
32 slides from Maia Biotechnology's investor presentation, Nov 8, 2024
Slide 1: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA November 2024
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS MAIA NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies
Slide 3: Investment Profile
INVESTMENT PROFILE New science for cancer therapy: dual MOA telomere targeting and immunogenicity. ¢ Lead molecule THIO in clinic; 2nd generation compounds in R&D Phase 2 trial THIO-101 nearing completion: THIO sequenced with CPI in NSCLC. ¢ Unprecedented disease control, response, post-therapy pati
Slide 4: Robust Pipeline
ROBUST PIPELINE THIO Telomere targeting agent THIO-101 NSCLC-2+ (THIO— Libtayo®) PHASE 1 | PHASE 2 Patient Enrollment Complete Ph 2 THIO-102 CRC, HCC, SCLC, ST (THIO CPT) panning THIO-103 NSCLC-1, SCLC-1 (THIO — CPI) 24 Generation Telomere targeting age MAIA-2021-020 Multiple Ind. enasiing MAIA-2022
Slide 5: Mission and Approach
NYSE American: MAIA MISSION AND APPROACH
Slide 6: Cancer as an age-related disease
Population aged >80 \ {\ —— expected to triple by 2050 O Cancer is the 142 . At age 90: most dominant million oy cus , age-related ] 40% will be diagnosed . 20% will die of it disease
Slide 7: THIO is the only direct telomere targeting anticancer agent in clinical development
PY THIO is the only direct telomere targeting anticancer agent in clinical development
Slide 8: THIO dual mechanism of action with checkpoint inhibitors
Immune Checkpoint Inhibitor THIO has a dual MoA: @ Telomere targeting ® Immunogenic effect v NO) (cemiplimab) (durvalumab) REGENERON AstraZeneca KEYTRUDA TEVIMBRA (pembrolizumab) (tistelizumab) BeiGene TECENTRIQ (atezolizumab) | | (ostarlimab-gxly) PDIVO. == @BAVENCIO (nivolumab) avelumab: Bristol M
Slide 9: THIO-101 NSCLC Trials - Rationale
THIO-101 NSCLC TRIALS - RATIONALE NYSE event AIA . Cycle 1 Cycle 2 ¢ THIO followed by CPI results in 60% 0 ; | complete response ee b —e— Atezolizuma * Only 2 cycles of therapy were ~e_THIO administered on weeks 1 and 2; no No cancer further therapy throughout the study 00 eT THIO ™ Atezo immune mem
Slide 10: THIO-101 Trial: Non-Small Cell Lung Cancer
NYSE American: MAIA THIO-101 TRIAL NON-SMALL CELL LUNG CANCER
Slide 11: Regeneron Clinical Supply Agreement
REGENERON CLINICAL SUPPLY AGREEMENT (es)! MAIA & REGENERON BIOTECHNOLOGY MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer
Slide 12: THIO-101 - Trial Design
THIO-101 — TRIAL DESIGN A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab) in NSCLC patients RESISTANT TO CHECKPOINT INHIBITORS Part A: Part B: Expansio Safety Efficacy / Safety / Dose Selection Registr
Slide 13: Patients' Survival by Line of Therapy
PATIENTS' SURVIVAL BY LINE OF THERAPY + Asof | Beptember 16, 2024, i i 19 patients had survival follow-up above 12 months: v 9in2L, 9 ongoing ¥ 10in3L, 8 ongoing v 1 patient 25 cycles of therapy i egend = Masai Im Follow: ° sraie Disease © Subject Third Li NYSE American: MAIA 1112 13 14 15 16 17 18
Slide 14: Treatment in Third-Line
TREATMENT IN THIRD-LINE NYSE American: MAIA Extended Survival 3 . * 20 subjects in 3L completed at least 1 post 2 o baseline assessment at time of cut-off ° Te i rt * 14/20 (70%) patients crossed 5.8 months OS > Oo 1o oOo} Oo Oo OO] 0 0 threshol meee a> * 17/20 (85%) crossed 2.5 months PFS threshold
Slide 15: Best 3L Results in the 180mg Dose
BEST 3L RESULTS IN THE 180MG DOSE NSCLC-3 - 180mg: * 6/8 (75%) patients crossed 5.8 months 7 OS threshold " * 7/8 ee") crossed 2.5 months PFS =e thres ¢ ORR some dose) 38% vs 6-10% chemotherapy? =e * DCR 88% vs 25-35% chemotherapy O44 i i Subject Median Survival Follow-Up (3L) 11.4 months lm Follow-
Slide 16: Expected Efficacy
EXPECTED EFFICACY THIO-101 THIO + Libtayo® NSCLC-3: Target Population * CPI+Platinum Resistant ¢ Prior treatment with Docetaxel DCR 88% ORR 38% PFS (median) 5.5 months OS (median) Not reached at 11.4 months median follow-up*
Slide 17: Planned Upcoming Trials
NYSE American: MAIA PLANNED UPCOMING TRIALS
Slide 18: THIO-102 Trial (Planned)
2 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Colorectal Cancer (CRC) Hepatocellula Carcinoma (HCC) Cc Solid Tumors? 1 Dose to be selected from THIO-101 stud
Slide 19: THIO-102 - Colorectal Rationale
THIO-102 — COLORECTAL RATIONALE 8101 oGy NYSE American: MAIA . 700 * THIO followed by CPI results in 100% =~ 600 eo Gontrol complete response = —e-Atezolizumab £& 500 —e—THIO * Only 2 cycles of therapy were 2 400 administered on weeks 1 and 2; no = cog TOT THIO > Atezo further therapy throughout the
Slide 20: SCLC and HCC preclinical models
) American: MAIA, SCLC 1500 1250 1000 —e—Control —e—Pembro > THIO —e—THIO > Pembro Tumor Volume (mm3) sl a Oo 0 5 10 15 20 25 Days After Tumor Inoculation THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model Treatment wi
Slide 21: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS -= Control ¢ THIO achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models 3 é =) ira 100% CR Tumor Volume (mm?) 0« 0 5 1015202530354045 Days after tumor inoculation
Slide 22: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated ¢ Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented ¢ Administration of THIO alone and in comb
Slide 23: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO SCLCFirstLine [isi (ex NSCLC First Line |Mia si (ey: Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 Immune Activation THIO-101
Slide 24: Investment Opportunity
NYSE American: MAIA INVESTMENT OPPORTUNITY
Slide 25: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY Goal: New Chemical Entity (NCE) Marketing Exclusivity e ¢ THIO has never been previously approved by the FDA for commercialization ¢ Robust exclusivity ¢ US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for THIO ¢ 5 issued pate
Slide 26: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Vlad Vitoc, MD, MBA Founder and CEO * 24+ years in Oncology Pharma/ Biotech: Commercial, Medical * 12 compounds launched across 20+ tumor types ¢ Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), Incyte (Jakafi) tb Nov
Slide 27: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY G Developing agents for the top tumor Checkpoint Inhibitors Market types markets globally 2023 Sales ($B) NSCLC (#1 WW ) HCC Mortality: 1.7M / Sales: $34B Mortality: 0.8M / Sales: $3B CRC (#2 WW) SCLC Mortality: 1.0M / Sales: $20B Mortality: 0.3M / Sales: $2B $46B CPIs
Slide 28: Comparable Companies
COMPARABLE COMPANIES NYSE American: MAIA ¢ On June 3, 2022, Bristol Myers Squibb (BMS) announced the acquisition of Turning Point Therapeutics in an all-cash transaction for $4.1B in equity value * On October 9, 2023, BMS acquired Mirati for $4.8B in cash, plus up to $1B in contingent value right *
Slide 29: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES NYSE American: MAIA % Major inflection points * 2024 2025 2026 THIO-101 Early Part B Part B Part B Part C Part C Filing for Potential Ph2 Efficacy Efficacy Long-term Full Efficacy Enrollment IS Accelerated NSCLC-2+ Update (ASCO) Efficacy Efficacy Update Complete app
Slide 30: Thank You
BIOTECHNOLOGY THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, I 444 West Lake Street, Suite 1700 Chicago, IL 60606 BIOTECHNOLOGY NYSE American: MAIA
Slide 31: Appendix
NYSE American: MAIA APPENDIX
Slide 32: U.S. FDA Granted Orphan Drug Designations to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS TO THIO The FDA’s Orphan Drug Act of 1983 is designed to incentivize the Vl of th - ne that d det som Ear dt of (orphan) di conditions Rare disease - affects fewer than 200,000 people total in the U.S, or if the cost of developing a drug and making it avai
MAIA Biotechnology — Investor Presentation (November 2024) on 6ix